LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

Search

AbbVie Inc

Gesloten

SectorGezondheidszorg

220.72 1.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

219.72

Max

221.33

Belangrijke statistieken

By Trading Economics

Inkomsten

-348M

941M

Verkoop

2.1B

15B

K/W

Sectorgemiddelde

106.502

35.69

EPS

2.97

Dividendrendement

2.91

Winstmarge

6.101

Werknemers

55,000

EBITDA

-56M

4.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.46% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.91%

3.08%

Volgende Winsten

29 okt 2025

Volgende dividenddatum

14 nov 2025

Volgende Ex Dividend datum

15 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

57B

393B

Vorige openingsprijs

219.57

Vorige sluitingsprijs

220.72

Nieuwssentiment

By Acuity

12%

88%

14 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

AbbVie Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 aug 2025, 13:50 UTC

Acquisities, Fusies, Overnames

AbbVie to Buy Investigational Major Depressive Disorder Drug for Up to $1.2 Billion

31 jul 2025, 12:46 UTC

Winsten

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30 jun 2025, 13:02 UTC

Acquisities, Fusies, Overnames

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

12 sep 2025, 13:57 UTC

Winsten

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

25 aug 2025, 13:01 UTC

Acquisities, Fusies, Overnames

AbbVie: Gilgamesh Deal Includes Upfront Payment, Development Milestones >ABBV

25 aug 2025, 13:01 UTC

Acquisities, Fusies, Overnames

AbbVie to Acquire Gilgamesh's Bretisilocin Program for Up to $1.2 Billion >ABBV

25 aug 2025, 12:59 UTC

Acquisities, Fusies, Overnames

AbbVie Gilgamesh's Bretisilocin in Development for Moderate-To-Severe Major Depressive Disorder >ABBV

25 aug 2025, 12:59 UTC

Acquisities, Fusies, Overnames

AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin >ABBV

19 aug 2025, 12:56 UTC

Acquisities, Fusies, Overnames

AbbVie Completes Acquisition Of Capstan Therapeutics >ABBV

31 jul 2025, 12:08 UTC

Winsten

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31 jul 2025, 11:46 UTC

Winsten

AbbVie Raises FY Outlook

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q Adj EPS $2.97 >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q EPS 52c >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q Rev $15.42B >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31 jul 2025, 11:44 UTC

Winsten

AbbVie 2Q Net $938M >ABBV

30 jun 2025, 12:47 UTC

Acquisities, Fusies, Overnames

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 jun 2025, 12:33 UTC

Acquisities, Fusies, Overnames

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 jun 2025, 12:33 UTC

Acquisities, Fusies, Overnames

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 jun 2025, 12:32 UTC

Acquisities, Fusies, Overnames

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 jun 2025, 12:31 UTC

Acquisities, Fusies, Overnames

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 mei 2025, 09:30 UTC

Top Nieuws

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 apr 2025, 12:44 UTC

Winsten

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 apr 2025, 09:33 UTC

Winsten

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr 2025, 16:03 UTC

Winsten

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

Peer Vergelijking

Prijswijziging

AbbVie Inc Prognose

Koersdoel

By TipRanks

7.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 237.06 USD  7.46%

Hoogste 270 USD

Laagste 204 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor AbbVie Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

21 ratings

15

Buy

6

Hold

0

Sell

Technische score

By Trading Central

180.37 / 195.54Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

14 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
help-icon Live chat